Hizentra (CSL Behring AG)
Welcome to the PulseAid listing for the Hizentra drug offered from CSL Behring AG. This Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Antigen Neutralization [MoA],Immunoglobulins [Chemical/Ingredient] pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.
LABELER NAME / MANUFACTURER: | CSL Behring AG |
NON-PROPRIETARY NAME: | HUMAN IMMUNOGLOBULIN G |
SUBSTANCE NAME: | HUMAN IMMUNOGLOBULIN G |
TYPE: | PLASMA DERIVATIVE |
PHARMA CLASS: | Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Antigen Neutralization [MoA],Immunoglobulins [Chemical/Ingredient] |
ROUTE: | SUBCUTANEOUS |
DOSAGE FORM: | LIQUID |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2011-10-03 |
END MARKETING DATE: | 0000-00-00 |
Hizentra PLASMA DERIVATIVE Details:
Item Description | Hizentra from CSL Behring AG |
LABELER NAME: | CSL Behring AG |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 0.2(g/mL) |
START MARKETING DATE: | 2011-10-03 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 44206-451_414ab6b7-15a9-4b09-9715-82cef5cb78cf |
PRODUCT NDC: | 44206-451 |
APPLICATION NUMBER: | BLA125350 |
Other HUMAN IMMUNOGLOBULIN G Pharmaceutical Manufacturers / Labelers: